Update on actinic keratosis in clinical trial experience with imiquimod

C. Ferrándiz

doi:10.1111/j.1365-2133.2007.08270.x

Update on actinic keratosis in clinical trial experience with imiquimod

C. Ferrándiz

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

11 Citations (Scopus)

Abstract

Actinic keratoses (AK) is a sun induced cutaneous lesion, currently considered as a squamous cell carcinoma in situ that has the potential to progress to invasive SCC. To treat them, numerous, ablative and no ablative, therapeutic approaches exist. Among them, imiquimod, a toll like receptor agonist, recently approved to treat them in the US and Europe, has demonstrated to be effective and safe with an acceptable tolerability in the treatment of these lesions. In this article the results of several high quality RCT are analysed. © 2007 The Author.

Original language	English
Pages (from-to)	32-33
Journal	British Journal of Dermatology
Volume	157
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1111/j.1365-2133.2007.08270.x
Publication status	Published - 1 Dec 2007

Keywords

Actinic keratosis
Imiquimod

Access to Document

10.1111/j.1365-2133.2007.08270.x

Fingerprint Dive into the research topics of 'Update on actinic keratosis in clinical trial experience with imiquimod'. Together they form a unique fingerprint.

Cite this

@article{5a35e39f28cc4cbf81e2cc853c4958ff,

title = "Update on actinic keratosis in clinical trial experience with imiquimod",

abstract = "Actinic keratoses (AK) is a sun induced cutaneous lesion, currently considered as a squamous cell carcinoma in situ that has the potential to progress to invasive SCC. To treat them, numerous, ablative and no ablative, therapeutic approaches exist. Among them, imiquimod, a toll like receptor agonist, recently approved to treat them in the US and Europe, has demonstrated to be effective and safe with an acceptable tolerability in the treatment of these lesions. In this article the results of several high quality RCT are analysed. {\textcopyright} 2007 The Author.",

keywords = "Actinic keratosis, Imiquimod",

author = "C. Ferr{\'a}ndiz",

year = "2007",

month = dec,

day = "1",

doi = "10.1111/j.1365-2133.2007.08270.x",

language = "English",

volume = "157",

pages = "32--33",

journal = "British Journal of Dermatology",

issn = "0007-0963",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Update on actinic keratosis in clinical trial experience with imiquimod

AU - Ferrándiz, C.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Actinic keratoses (AK) is a sun induced cutaneous lesion, currently considered as a squamous cell carcinoma in situ that has the potential to progress to invasive SCC. To treat them, numerous, ablative and no ablative, therapeutic approaches exist. Among them, imiquimod, a toll like receptor agonist, recently approved to treat them in the US and Europe, has demonstrated to be effective and safe with an acceptable tolerability in the treatment of these lesions. In this article the results of several high quality RCT are analysed. © 2007 The Author.

AB - Actinic keratoses (AK) is a sun induced cutaneous lesion, currently considered as a squamous cell carcinoma in situ that has the potential to progress to invasive SCC. To treat them, numerous, ablative and no ablative, therapeutic approaches exist. Among them, imiquimod, a toll like receptor agonist, recently approved to treat them in the US and Europe, has demonstrated to be effective and safe with an acceptable tolerability in the treatment of these lesions. In this article the results of several high quality RCT are analysed. © 2007 The Author.

KW - Actinic keratosis

KW - Imiquimod

U2 - 10.1111/j.1365-2133.2007.08270.x

DO - 10.1111/j.1365-2133.2007.08270.x

M3 - Review article

VL - 157

SP - 32

EP - 33

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - SUPPL. 2

ER -